Microscopic Polyangiitis (MPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Microscopic Polyangiitis (MPA) Market Outlook

Thelansis’s “Microscopic Polyangiitis (MPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microscopic Polyangiitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Microscopic Polyangiitis (MPA) Overview

Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys, lungs, and peripheral nerves, although muscle involvement with myalgia is rare and typically diagnosed through muscle biopsy specimens showing necrotizing vasculitis. ANCA is present in only 70% of MPA cases at diagnosis, and most instances of limited MPA lack ANCA altogether. This suggests the involvement of other factors in its development, including:

1. Infectious Causes: There is substantial overlap in the clinical presentation of infectious diseases and MPA, leading to this association. Chronic nasal carriage of Staphylococcus aureus has been implicated in relapsing granulomatosis with polyangiitis (GPA).
2. Drugs: Several drugs, such as hydralazine, thionamides, sulfasalazine, and minocycline, have been linked to the occurrence of ANCA-associated vasculitis.
3. Genetic Factors: genes like HLA-DP, HLA-DR3, and alpha-1 antitrypsin contribute to the pathogenesis of ANCA-associated vasculitides.

MPA has also been associated with silica exposure, which can induce autoimmunity in individuals with genetic predispositions. Microscopic Polyangiitis (MPA) can affect individuals of all age groups but typically develops around age 50. It can affect both genders, with men potentially being more susceptible. Although more common among Caucasians, MPA can affect people of any race or ethnic background.

• Approximately 90% of MPA patients experience improvement with appropriate treatment, and roughly 75% achieve complete remission. The condition has a 5-year survival rate of 75%.
• The estimated prevalence of Microscopic Polyangiitis (MPA) in the United States ranges from 2.5 to 3.5 cases per 100,000 individuals, with an incidence ranging from 0.75 to 1.2 cases per 100,000 persons.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: